PE ratio relative to earnings growth — is the valuation justified?
| Symbol | Company | PEG | P/E | Growth | vs EXEL |
|---|---|---|---|---|---|
| ACAD | ACADIA Pharmaceuticals Inc. | 0.17 | 11.7 | 69.3% | -51% |
| INCY | Incyte Corporation | 0.25 | 15.7 | 62.7% | -27% |
| VRTX | Vertex Pharmaceuticals Incorporated | 3.67 | 30.0 | 8.2% | +966% |
| BMRN | BioMarin Pharmaceutical Inc. | 5.62 | 151.3 | 26.9% | +1530% |